The National Comprehensive Cancer Network issued updated guidelines for prostate cancer, including new information about the role of family history, specific mutations, and microsatellite instability testing.
Commercial payers are spending almost twice as much on chemotherapy administered in hospital outpatient departments compared with therapy administered in physician offices.
A study to be presented at the BMT Tandem Meetings found no difference in OS for patients aged 55-64 years compared with those aged 65 years and older with non-Hodgkin lymphoma who underwent alloHCT.
The National Comprehensive Cancer Network released updated guidelines for a variety of B-cell lymphomas, including follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma.
FDA-approved CAR T-cell therapies may be associated with high costs, but the therapies are priced in alignment with their clinical value, according to an Institute for Clinical and Economic Review evidence report.
Rates of Merkel-cell carcinoma in the United States have increased significantly in the past decade due largely to the aging population, a new study confirms.
Health care providers and patients have identified a need for further resources to support survivorship care in gynecologic oncology, according to a presentation given at the 2018 ASCO Cancer Survivorship Symposium.
A recent study evaluated health care utilization and costs of pulmonary arterial hypertension in a real-world setting by comparing periods before and after treatment initiation.
A systematic review presented at the 2018 ASCO Cancer Survivorship Symposium determined whether survivorship care plans have a positive impact on health outcomes and health care delivery.
New recommendations from the Hematology/Oncology Pharmacy Association (HOPA) support dose-rounding of up to 10% for biologic and cytotoxic anticancer agents.